TIDMETX
RNS Number : 5993T
e-Therapeutics plc
09 January 2017
e-Therapeutics plc
("e-Therapeutics" or the "Company")
Appointment of Amgen Executive Director as Chief Executive
Oxford, UK - 9 January 2017 - e-Therapeutics plc (AIM: ETX), the
drug discovery company, announces that it has appointed Dr. Raymond
Barlow as Chief Executive Officer. Dr. Barlow will take up the role
on or before 1 May 2017, at which point he will be appointed to the
e-Therapeutics Board of Directors.
Dr. Barlow, aged 48, is currently Executive Director of
Corporate Development at Amgen Inc. based in Switzerland. He brings
to e-Therapeutics broad experience of drug discovery, develop-ment
and commercialization, acquired through regional and global roles
in the biotech and pharmaceutical sector. His previous
responsibilities have included scientific, business and corporate
roles with Astra Zeneca, Crucell and Johnson and Johnson. He will
be relocating to Oxford.
e-Therapeutics' Chairman, Mr. Iain Ross said:
"On behalf of the team, I welcome Ray to e-Therapeutics. He
joins the Company at an exciting time and is a consummate business
professional who brings a wealth of relevant experience from the
international pharmaceutical and biotech sector. I am confident
that, as CEO, he will lead us through the next stage of the
Company's development and achieve both our short and long term
goals.
"I would also like to take this opportunity to thank the
e-Therapeutics team for the tremendous effort they have made over
the last six months whilst the business has been in transition and
has refocused its strategy."
Ray Barlow added, "As our understanding of human disease and
genetics deepens, it is clear that that the traditional
"reductionist" approach to drug discovery is only potentially part
of the solution. I believe that e-Therapeutics'
computational-based, network biology approach provides a valuable,
productive and differentiated means to create novel medicines to
treat inherently complex diseases.
"Once I'm on board, my aim is to continue building the network
pharmacology platform, generating additional supporting data for
the internal programmes, and on communicating to the industry the
utility of this approach in addressing some of the biggest
challenges it faces in treating serious and debilitating diseases.
I am looking forward to working with the e-Therapeutics' team and
driving the Company forward to reach its full potential."
Background Information on Dr Raymond Barlow
Having completed a BSc in Chemistry from Leeds University in
1990, Dr. Barlow moved to the University of Manchester from where
he gained a PhD in Chemistry in 1994. He then spent a year at
McGill University, Montreal as a post-doctoral fellow before
entering the pharmaceutical industry as a senior scientist with
Zeneca in Pharmaceutical R&D's Technology Access and Strategic
Alliances team, of which he later became Team Leader in 1998.
Following the merger with Astra, he became a Global Manager in
the Discovery and Development function, in-licensing technologies
and working on the development of a range of molecules, including
those in oncology, cardiovascular, respiratory and inflammatory
disease areas.
Upon completion of a year as a Senior Business Analyst he was
appointed Director of Corporate Development, reporting into
AstraZeneca's (AZ) London HQ. In this role he was involved in a
number of transactions and was part of the team responsible for
shaping AZ's strategy with the Board, including its move into
biologics. During this period he graduated from Manchester Business
School with an MBA and in 2004 he stepped out of the Business
Development function into a Regional commercial leadership role in
Brussels covering 14 countries in CEE and Russia.
After 10 years with AZ, Ray moved into the biotech sector
working in senior business development roles for Microscience
Limited and Emergent Solutions Inc (EBS: NASDAQ). During this
period Ray out-licensed a portfolio of Meningitis B assets to
Sanofi and was involved with the team that successfully listed EBS
on NASDAQ. Ray then spent five years running his own business (BD
Solutions Limited) focused upon aiding clients on corporate
development and commercialisation projects. During this period he
was CEO of Asterion, and delivered deals with Genzyme and
Ipsen.
In 2010, he joined Crucell and was instrumental in the sale to
Johnson & Johnson for whom he worked on a wide range of
infectious disease and vaccine deals, before joining Amgen in 2012.
At Amgen he has also completed numerous deals including
immuno-oncology deals with Boehringer Ingelheim and Genenta,
international commercial deals with GSK and Mitsubishi Tanabe as
well as playing a key part in the acquisition of Onyx and Dezima
Pharma BV.
Additional Information
The following information is being disclosed pursuant to Rule 17
and paragraph (g) of Schedule 2 of the AIM Rules for Companies.
Full name: Raymond John Barlow.
Dr Barlow does not hold any shares in the Company.
In the previous five years, Dr Barlow was a director of BD
Solutions (Partners in Corporate Growth) Limited.
-Ends-
For more information, please contact:
e-Therapeutics plc Tel: +44 (0)1993 883 125
Iain Ross, Chairman www.etherapeutics.co.uk
Steve Medlicott, Finance Director
Numis Securities Limited Tel: +44 (0) 207 260 1000
Michael Meade / Freddie Barnfield www.numis.com
(Corporate Finance)
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457 2020
Melanie Toyne Sewell / Deborah Bell Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a
proprietary discovery platform based on advances in network
pharmacology and chemical biology. The Company is applying its
platform to the discovery of new drug candidates. The therapeutic
focus of the Company's activity is in immuno-oncology, addressing
drug resistance in targeted cancer therapies and anti-infectives.
The platform is highly productive, yielding multiple potent and
selective molecules at a much higher rate and more quickly than is
reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets,
ETS2300, telomerase inhibition in anti-cancer; ETS3100, small
molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway
inhibition; ETS5200, broad spectrum antivirals together with two
immuno-oncology checkpoint projects.
The Company is fully funded to advance its drug discovery
programmes. It is based in Oxford, UK. For more information, visit
www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABLGDBSSGBGRI
(END) Dow Jones Newswires
January 09, 2017 02:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024